Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIOPIX DNA TECHNOLOGY S.A. is active in the Biotechnology & Pharmaceuticals technology area, with 1 pending office action currently on record. This action is assigned to 1 distinct examiner, indicating a singular focus for the company's active patent prosecution. The portfolio is situated within 1 distinct art unit, which provides a consistent regulatory environment for their technical innovations.
The busiest examiner for this portfolio is YU, TIAN NMN, who is responsible for the 1 busiest examiner pending action. Because there is only 1 distinct examiner, the company's prosecution strategy is centralized around the feedback and requirements of this one individual. This 1:1 ratio between pending actions and examiners allows for a highly specific and focused approach to resolving the current legal challenge.
In the Biotechnology & Pharmaceuticals sector, the examination process is often rigorous, but BIOPIX DNA TECHNOLOGY S.A. only has 1 pending office action to manage. The concentration in 1 distinct art unit means that the practitioner does not need to account for different divisional interpretations. This streamlined setup allows the company to focus its resources entirely on addressing the 1 pending office action under the review of YU, TIAN NMN.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, TIAN NMN | 1 | 55.6% | +19.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17282729 | METHOD AND APPARATUS FOR PERFORMING A REAL-TIME COLORIMETRIC NUCLEIC ACID AMPLIFICATION ASSAY | YU, TIAN NMN | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17282729 | METHOD AND APPARATUS FOR PERFORMING A REAL-TIME COLORIMETRIC NUCLEIC ACID AMPLIFICATION ASSAY | YU, TIAN NMN | 1681 | §103 | Final Rejection | 9d overdue | Pending | Apr 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOPIX DNA TECHNOLOGY S.A. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tian Nmn Yu has the most, with 1 of BIOPIX DNA TECHNOLOGY S.A.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
